1.The changes and clinical significance of PAI-1,TGF-β,VEGF,and IL-6 in serum and pleural effusion of patients with tuberculous pleurisy and pleural fibrosis
Xiaoguang ZHANG ; Pei LYU ; Jiangyan GAO ; Liangjing SHI ; Yongjun WANG ; Liheng ZHENG ; Hui LIU
International Journal of Laboratory Medicine 2024;45(15):1828-1833,1838
Objective To investigate the changes and clinical significance of plasminogen activator inhibi-tor-1(PAI-1),transforming growth factor-β(TGF-β),vascular endothelial growth factor(VEGF),and inter-leukin-6(IL-6)in patients with tuberculous pleurisy and pleural fibrosis.Methods A total of 103 patients with tuberculous pleurisy and pleural fibrosis who were treated in a hospital from July 2020 to July 2023 were selected as the research subjects.After 2 weeks of treatment,they were divided into a significant effect group and a non-significant effect group based on the therapeutic efficacy of glucocorticoid treatment.The levels of PAI-1,TGF-β,VEGF,and IL-6 in serum and pleural effusion were compared before treatment,after 1 and 2 weeks of treatment.The correlation between the levels of PAI-1,TGF-β,VEGF,and IL-6 in serum and pleural effusion and the therapeutic efficacy was analyzed by Spearman correlation analysis.Pearson correlation analy-sis was used to analyze the correlation between the levels of PAI-1,TGF-β,VEGF,and IL-6 in serum and pleu-ral effusion and the levels of these indicators in pleural effusion after 2 weeks of treatment.A receiver operat-ing characteristic curve was drawn to analyze the predictive value of the levels of PAI-1,TGF-β,VEGF,and IL-6 in serum and pleural effusion for the efficacy of tuberculous pleurisy and pleural fibrosis patients after 1 and 2 weeks of treatment.Results The levels of PAI-1,TGF-β,VEGF,and IL-6 in serum and pleural effusion after 1 and 2 weeks of treatment in both groups were lower than those before treatment,and the levels of PAI-1,TGF-β,VEGF,and IL-6 in serum and pleural effusion after 1 and 2 weeks of treatment in the significant effect group were lower than those in the non-significant effect group,with statistically significant differences(P<0.05).The levels of PAI-1,TGF-β,VEGF,and IL-6 in serum and pleural effusion after 1 and 2 weeks of treatment were negatively correlated with the efficacy(P<0.05).The levels of PAI-1,TGF-β,VEGF,and IL-6 in serum and pleural effusion after 2 weeks of treatment were positively correlated(r=0.761,0.783,0.812,0.741,all P<0.05).The area under the curve(AUC)of combined detection of serum and pleural effusion in-dicators after 1 and 2 weeks of treatment was greater than the AUC of individual indicators(P<0.05).Con-clusion The levels of PAI-1,TGF-β,VEGF,and IL-6 in serum and pleural effusion of patients with tubercu-lous pleurisy and pleural fibrosis are related to the efficacy of treatment.The combined detection of PAI-1,TGF-β,VEGF,and IL-6 in serum and pleural effusion has good predictive value and can provide reference for clinical intervention.
2.Serum proteomics in patients with cognitive impairment at high altitude
Journal of Apoplexy and Nervous Diseases 2024;41(12):1073-1078
Objective To identify the differentially expressed proteins associated with cognitive impairment between the high-altitude population and the plain population, and to investigate the biological functions and signaling pathways of the differentially expressed proteins. Methods A total of 30 individuals living in the plain area (with an altitude of 400 m) and 30 individuals living in the high-altitude area (with an altitude of 3 960 m) were enrolled as plain group and high-altitude group, respectively, and general information was collected from all subjects. Montreal Cognitive Assessment (MoCA) was used to assess cognitive function. Blood samples were collected from each group, and the tims TOF Pro mass spectrometer was used to measure the serum levels of proteins after centrifugation. SPSS 25.0 was used for statistical analysis to investigate he association between proteomics and cognitive impairment. Results The results of MoCA assessment for both groups showed that the high-altitude group had a significantly lower MoCA score than the plain group, suggesting that there was significant cognitive impairment in the high-altitude group, with the main manifestation of impairment in visual space/executive ability, attention, delayed memory, and orientation. The proteomic analysis of serum samples from the subjects identified 169 differentially expressed proteins (84 upregulated proteins and 85 downregulated proteins), among which 39 proteins were associated with cognitive impairment. The enrichment analysis of the differentially expressed proteins showed that these differentially expressed proteins were involved in the regulation of multiple signaling pathways and metabolic pathways. Conclusion Significant cognitive impairment is observed in the high-altitude population, and there are differentially expressed proteins associated with cognitive function between the high-altitude population and the plain population.
Proteomics